Acamprosate

Generic Name
Acamprosate
Brand Names
Campral
Drug Type
Small Molecule
Chemical Formula
C5H11NO4S
CAS Number
77337-76-9
Unique Ingredient Identifier
N4K14YGM3J
Background

Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.
...

Indication

Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.

Associated Conditions
Alcohol Abstinence, Alcohol Dependency
Associated Therapies
-
Clinical Trials
Related News

Biomarker Study of Acamprosate in Schizophrenia

Phase 4
Completed
Conditions
Schizoaffective Disorder
Schizophrenia
Interventions
Drug: Acamprosate
First Posted Date
2008-06-02
Last Posted Date
2019-09-25
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
36
Registration Number
NCT00688324
Locations
🇺🇸

VA Maryland Health Care System, Baltimore, Maryland, United States

🇺🇸

Keypoint Community Mental Health Centers- Dundalk, Baltimore, Maryland, United States

🇺🇸

Maryland Psychiatric Research Center, Baltimore, Maryland, United States

and more 1 locations

Acamprosate: Genes Associated With Response

Completed
Conditions
Alcoholism
Interventions
Drug: acamprosate
First Posted Date
2008-04-21
Last Posted Date
2013-03-22
Lead Sponsor
Mayo Clinic
Target Recruit Count
485
Registration Number
NCT00662571
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

Phase 2
Completed
Conditions
Alcoholism
Interventions
Drug: Placebo
Drug: Acamprosate
Drug: Naltrexone
First Posted Date
2008-04-11
Last Posted Date
2017-03-29
Lead Sponsor
The Scripps Research Institute
Target Recruit Count
68
Registration Number
NCT00656630
Locations
🇺🇸

The Scripps Research Institute, La Jolla, California, United States

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

First Posted Date
2008-04-10
Last Posted Date
2023-08-01
Lead Sponsor
University of New Mexico
Registration Number
NCT00655967
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Not Applicable
Withdrawn
Conditions
Parkinson's Disease
First Posted Date
2008-03-21
Last Posted Date
2015-11-13
Lead Sponsor
Baylor College of Medicine
Registration Number
NCT00640952
Locations
🇺🇸

PDCMDC 6550 Fannin, Suite 1801, Houston, Texas, United States

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

First Posted Date
2008-01-31
Last Posted Date
2012-07-03
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Target Recruit Count
37
Registration Number
NCT00605904
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Clinical Trial of Acamprosate for Tinnitus

Phase 1
Completed
Conditions
Tinnitus
Interventions
Drug: Placebo
Drug: Acamprosate
First Posted Date
2008-01-17
Last Posted Date
2016-11-08
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
154
Registration Number
NCT00596531
Locations
🇺🇸

OHSU, Portland, Oregon, United States

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

Not Applicable
Completed
Conditions
Anxiety
Interventions
Drug: Acamprosate
First Posted Date
2008-01-11
Last Posted Date
2014-12-18
Lead Sponsor
State University of New York - Upstate Medical University
Target Recruit Count
13
Registration Number
NCT00591565
Locations
🇺🇸

SUNY Upstate Medical University Psychiatry Dept., Syracuse, New York, United States

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

First Posted Date
2007-12-12
Last Posted Date
2017-03-24
Lead Sponsor
NYU Langone Health
Target Recruit Count
72
Registration Number
NCT00571922
Locations
🇺🇸

VA New York Harbor Healthcare System, MHAD clinic, New York, New York, United States

Acamprosate in the Treatment of Pathological Gambling

Phase 4
Completed
Conditions
Pathological Gambling
Interventions
Drug: acamprosate
First Posted Date
2007-12-11
Last Posted Date
2017-05-25
Lead Sponsor
University of Iowa
Target Recruit Count
26
Registration Number
NCT00571103
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy